Navigation Links
3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
Date:3/19/2008

SHENYANG, China, March 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) (''3SBio'' or the ''Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Dr. David Chen to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Dr. Chen most recently held the position of Vice President of Business Development at 3SBio.

Since joining 3SBio in June 2007, Dr. Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical companies in major markets worldwide. In addition to his existing responsibilities, Dr. Chen will assume oversight of commercial operations including commercial strategy, medical and regulatory, government affairs, and export. He will be based in Beijing, China.

Dr. Jing Lou, CEO of 3SBio, commented, ''I am very pleased to announce the promotion of David Chen to the position of Chief Operating Officer. Since assuming the role of VP of Business Development, David has quickly demonstrated his leadership skills and has played a critical role in planning and executing our future growth strategies and partnering initiatives, helping to establish relationships with a number of potential partners around the world. His in-depth understanding of the Chinese pharmaceutical market place combined with his significant operating experience with multinational pharmaceutical companies in the US make him the ideal candidate to assume this newly created position. I look forward to working together with David as we help drive the next phase of 3SBio's growth.''

Prior to joining 3SBio, Dr. Chen, 42, held various managerial positions in the US pharmaceutical industry, including business development, sales and marketing, market research, new product development and R&D portfolio management both with Eli Lilly and GlaxoSmithKline. Prior to his experience in the US, Dr. Chen was a practicing orthopedic surgeon at Shanghai Medical University from 1989 to 1992. He received a medical degree from the First Military Medical University in Guangzhou, China, and earned a Masters Degree in Business Administration from the Darden School of Business at the University of Virginia.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

For more information, please contact:

Investor Contact:

Kevin Teo, CFO

3SBio Inc.

Tel: +86-24-2581-1820

Email: ir@3sbio.com

Investor Relations(HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Email: 3sbio@taylor-rafferty.com

Investor Relations(US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Email: 3sbio@taylor-rafferty.com

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350

Email: 3sbio@taylor-rafferty.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
2. 3SBio Inc. Announces Change to the Board of Directors
3. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
4. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
7. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
8. 3SBio Inc. to Hold Annual General Meeting
9. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- The National Pharmaceutical Council (NPC) today announced that Ipsen ... as its newest member. David Cox , PhD, ... America ), will serve as his company,s representative ... to have Ipsen and Dr. Cox join NPC as ... welcome their insights in helping us identify and address ...
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just Biotherapeutics, ... solution, LabKey Biologics . Built in collaboration with Just and designed with ... provides drug research teams tools for biological entity registration, assay data integration, and ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: ... to report compelling safety and clinical data from its phase ... 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for ... ... a complete safety profile at 6 months and showed no ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation ... cancer, autoimmune disease and more through a single-cell precision engineering platform, today announced ... platform developed in the laboratory of Dr. James Heath at the California ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
Breaking Biology News(10 mins):